Pancreatic endocrine carcinoma
MONDO:0005893An aggressive, high-grade and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the pancreas. The mitotic count is more than 20 per 10 HPF. According to the size of the malignant cells, the prominence of the nucleoli, and the amount of cytoplasm, it is classified either as small or large cell neuroendocrine carcinoma.
Also known as: Pancreatic Neuroendocrine cancer, carcinoma of endocrine pancreas, carcinoma, islet cell, malignant, endocrine pancreas carcinoma, high grade pancreatic neuroendocrine carcinoma, high-grade pancreatic neuroendocrine carcinoma, islet cell cancer, islet cell carcinoma
2919 clinical trials for this condition and its sub-types, 12 tagged with Pancreatic endocrine carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Pancreatic endocrine carcinoma
-
Radioactive therapy vs chemotherapy: which works better for pancreatic NETs?
Disease control OngoingThis trial compares two treatment approaches for pancreatic neuroendocrine tumors that have spread or cannot be removed surgically. One group receives lutetium Lu 177 dotatate, a radioactive drug that targets tumor cells, while the other receives a combination of chemotherapy dru…
Phase 2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New chemo combo tested for rare gut cancers – results disappoint
Disease control OngoingThis phase 2 trial tested whether a combination of temozolomide and capecitabine works better than the standard cisplatin and etoposide for people with advanced, hard-to-treat gastrointestinal neuroendocrine carcinomas. The study enrolled 67 participants whose cancer had spread o…
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Immunotherapy duo takes on rare tumors
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill shows promise against tough cancers in early trial
Disease control OngoingThis Phase 2 trial tests an oral drug called ESK981 in people with advanced pancreatic cancer, neuroendocrine tumors, or neuroendocrine prostate cancer. The goal is to see if the drug can keep the cancer from growing for at least 4 months. Participants take the drug for 5 days, t…
Phase 2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Could a chemo combo slow pancreatic tumor growth?
Disease control OngoingThis study tested whether adding capecitabine to the chemotherapy drug temozolomide helps people with advanced pancreatic neuroendocrine tumors live longer without their cancer growing. A total of 144 adults with tumors that could not be removed by surgery took part. The goal was…
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New hope for rare pancreatic cancer: experimental drug enters trial
Disease control By invitation onlyThis study tests a drug called lurbinectedin in people with high-grade pancreatic neuroendocrine tumors (a rare, fast-growing cancer) who have already tried standard treatments. The goal is to see if the drug can shrink tumors or stop them from growing. About 46 adults will take …
Phase 2 • Sponsor: National Cancer Center, Korea • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC